AGWCA
VKTX icon

Annis Gardner Whiting Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-700
Closed -$22.8K – 1216
2026
Q1 		$22.8K Buy
+700
New +$22.5K ﹤0.01% 703

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's VKTX Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 700 shares — an estimated $22.8K sold.

Annis Gardner Whiting Capital Advisors first reported a position in VKTX in Q1 2026 and held it in 1 quarter. The position peaked at $22.8K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 700 Viking Therapeutics shares in Q2 2026, an estimated $22.8K.
  • Annis Gardner Whiting Capital Advisors first reported a position in Viking Therapeutics in Q1 2026 and held it in 1 quarter.
  • Annis Gardner Whiting Capital Advisors's Viking Therapeutics position peaked at $22.8K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.